Please login to the form below

Not currently logged in
Email:
Password:

antiplatelet

This page shows the latest antiplatelet news and features for those working in and with pharma, biotech and healthcare.

New cancer drugs can’t quite plug the revenue hole at AZ

New cancer drugs can’t quite plug the revenue hole at AZ

Other bright spots for AZ included the continued growth if antiplatelet drug Brilinta (ticagrelor), up 18% to $609m, diabetes drug Farxiga (dapagliflozin) which leaped 36% to $639m, and new asthma drug

Latest news

More from news
Approximately 3 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Why health psychology is the answer to tackling adherence Why health psychology is the answer to tackling adherence

    In one recent programme that we developed on behalf of AstraZeneca, we assessed the reasons for low adherence in patients with acute coronary syndrome (ACS) who had been prescribed Oral Antiplatelet

  • Who tops the pharma list? Who tops the pharma list?

    The latter, an antiplatelet agent it co-marketed with Sanofi, enjoyed 2011 sales of $9.4bn - but, with Plavix accounting for more than a third of BMS revenues in 2010, the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics